

PROGRAMME OF LIVE SESSIONS: **CEST timing**

The programme below will take place live. This time schedule corresponds to **CEST timing**. [Click here: https://www.calculator.net/time-zone-calculator.html](https://www.calculator.net/time-zone-calculator.html) to adapt the CEST time schedule to your own time zone.

If you want to ask questions during the Panel Discussions and Round Tables or if you want to test your knowledge and vote during Interactive Case presentations and debates, please make sure that you join us at the times indicated below.

Please also note that the Meet the Expert sessions and the Mentored Poster Walk will take place 100% live. To interact you must be online at the times indicated in the programme below.

Thank you for joining us. We wish you a good meeting



E-Conference: How I Manage CAR-T Therapies and Bispecific Antibodies for My Patients September 6-9, 2021 - #ESHCart2021

Chairpersons: Peter Borchmann (Cologne), Ulrich Jäger (Vienna), Marie José Kersten (Amsterdam)

Monday, September 6, 2021

14:40-14:45 **Welcome: Peter Borchmann, Ulrich Jäger, Marie José Kersten**

SESSION I – Diffuse large B-cell Lymphoma: How to optimize the benefit of CAR T-cell therapy?

Chairs: Gilles Salles (New York) and Marie José Kersten (Amsterdam)

- | | | |
|-------------|---|---|
| 14:45-14:50 | Introduction | Gilles Salles (New York) and Marie José Kersten (Amsterdam) |
| 14:50-15:10 | Case-based lecture:
Real world data: patient selection and bridging strategies? | Catherine Thieblemont (Paris) |
| 15:10-15:20 | Interactive case:
Monitoring CAR expansion and persistence? | Peter Borchmann (Cologne) |
| 15:20-15:25 | <u>Brief oral communication</u>
<i>Longitudinal CAR T-Cell Detection and Quantification by Ddpcr in Cellular and Cell-Free DNA in Patients Treated with Tisagenlecleucel</i> | Adrian Minson (Melbourne) |
| 15:25-15:45 | Perspectives:
Ongoing clinical trials and developments in DLBCL | Gilles Salles (New York) |
| 15:45-16:05 | Case-based lecture:
Biology of CAR therapy and mechanisms of resistance | Robbie Majzner (Stanford) |
| 16:05-16:35 | Panel discussion | |
| 16:35-16:45 | Coffee Break | |

SESSION II – Diffuse large B-cell lymphoma: How to minimize potential risks of CAR T-cell therapy?

Chairs: Peter Borchmann (Cologne), Stephan Grupp (Philadelphia)

16:45-16:50	Introduction	Peter Borchmann (Cologne), Stephan Grupp (Philadelphia)
16:50-17:00	Interactive case: CRS grading and management	Ulrich Jäger (Vienna)
17:00-17:10	Interactive case: ICANS grading and management	Peter Schellongowski (Vienna)
17:10-17:30	Case-based lecture: Novel strategies to prevent/treat CRS/ICANS	Stephan Grupp (Philadelphia)
17:30-17:50	Case-based lecture: Hematotoxicity: early & late Cytopenia and Hypogammaglobulinaemia	Marion Subklewe (Munich)
17:50-18:10	Perspectives: Learning from doing?	Christian Chabannon (Marseille)
18:10-18:40	Panel discussion	

18:55-19:55 SATELLITE SYMPOSIUM

CAR-T cells in DLBCL: timing is key for success!

Chair: Sarah Jarvis (London)

Speakers: Georg Lenz (Münster), Bastian von Tresckow (Essen)

This symposium is organized and sponsored by Novartis

Tuesday, September 7, 2021

12:20-13:20 SATELLITE SYMPOSIUM

New era in the treatment of MM and NHL

Chair: Hermann Einsele (Würzburg)

Speakers: Hermann Einsele (Würzburg), Maria-Victoria Mateos (Salamanca), Catherine Thieblemont (Paris)

This symposium is organized and sponsored by Bristol Myers Squibb

13:30-14:30 SATELLITE SYMPOSIUM

Personalizing treatments for individual patients with multiple myeloma

Chair: Philippe Moreau (Nantes)

Speakers: Philippe Moreau (Nantes), Paula Rodríguez-Otero (Pamplona)

This symposium is supported by Janssen Oncology Pharmaceutical Companies of Johnson & Johnson

SESSION III – Multiple Myeloma: targeting BCMA with bispecifics and CARs

Chairs: Hermann Einsele (Würzburg), Maria Victoria Mateos (Salamanca)

14:40-14:45	Introduction	Hermann Einsele (Würzburg), Maria Victoria Mateos (Salamanca)
14:45-15:05	Interactive case: Multiple Myeloma	Maria Victoria Mateos (Salamanca)
14:05-15:10	<u>Brief oral communication</u> <i>Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) × CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results of a Phase 1, First-in-Human Study</i>	Niels W.C.J. van de Donk (Amsterdam)
15:10-15:30	Case-based lecture: BCMA targeted CAR T-cell therapy for multiple r/r MM	Sham Mailankody (New York)
15:30-15:35	<u>Brief oral communication</u> <i>Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy, in Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results from Cartitude-1</i>	Saad Z. Usmani (Charlotte)
15:35-15:55	Perspectives: Developments beyond targeting BCMA	Michael Hudecek (Würzburg)
15:55-16:00	<u>Brief oral communication</u> <i>Teclistamab and Talquetamab Modulate Levels of Soluble B-Cell Maturation Antigen in Patients with Relapsed and/or Refractory Multiple Myeloma</i>	Suzette Girgis (Spring House)
16:00-16:20	Interactive case: Multiple Myeloma	Maria Victoria Mateos (Salamanca)
16:20-16:45	Panel discussion	
16:45-16:50	Coffee break	
16:50-17:45	DEBATE 1 – The future of myeloma therapy: how can T-cell engagement be integrated into current treatment strategies? Chair: Maria Victoria Mateos (Salamanca)	
16:50-16:55	Introduction	Maria Victoria Mateos (Salamanca)
	Audience votes	
16:55-17:10	Bispecific antibodies	Hermann Einsele (Würzburg)
17:10-17:25	CARs	Sham Mailankody (New York)
	Audience votes again	
17:25-17:45	Discussion	
17:45-18:35	ROUNDTABLE 1 – Affordability of and access to CAR T-cell and bispecifics treatment Chair: Ulrich Jäger (Vienna)	
	Discussants: Carin Uyl-de Groot (Rotterdam), Ananda Plate (Munich), Bertram Glass (Berlin), Ana Hidalgo-Simon (Amsterdam), Emanuele Ostuni (Basel)	

18:35-18:50 MEET THE EXPERT'S FLASH TALKS

18:35-18:40	Neuroblastoma	Franco Locatelli (Rome)
18:40-18:45	CAR T-cells for solid childhood tumours	Concetta Quintarelli (Rome)
18:45-18:50	Making CAR T-cells last	Karin Straathof (London)

To learn more and get answers to all your questions, make sure you pre-register to join the live Meet the Expert session of your choice.

19:00-20:00 Simultaneous Meet the Expert Sessions:

1. Neuroblastoma	Franco Locatelli (Rome)
2. CAR T-cells for solid childhood tumours	Concetta Quintarelli (Rome)
3. Making CAR T-cells last	Karin Straathof (London)

Wednesday, September 8, 2021

13:55-14:35 WORKSHOP – Improving the Patient Journey
Chair: Michael Hudecek (Würzburg)

13:55-14:05 Introduction including short interview with a patient Marie José Kersten (Amsterdam)

14:05-14:35 Live discussion Ulrich Jäger (Vienna), Peter Borchmann (Cologne),
Marie José Kersten (Amsterdam), Jonathan Clark (London)

SESSION IV – Bispecific antibodies in the treatment of B-NHL
Chairs: Martin Hutchings (Copenhagen), Ulrich Jäger (Vienna)

14:40-14:45 Introduction Martin Hutchings (Copenhagen), Ulrich Jäger (Vienna)

14:45-14:55 Interactive case: Bispecifics post-CAR T Marion Subklewe (Munich)

14:55-15:00 Brief oral communication
Antitumor Activity and Safety Profile of Subcutaneous Epcoritamab in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Dose-Escalation Data from the Epcore NHL-1 Trial Pieterella Lugtenburg (Rotterdam)

15:00-15:20 Case-based lecture: Bispecifics in relapsed DLBCL? Stephan Schuster (Philadelphia)

15:20-15:40 Case-based lecture: Bispecifics in first line DLBCL? Richard Greil (Salzburg)

15:40-16:00 Case-based lecture: other lymphomas Martin Hutchings (Copenhagen)

16:00-16:30 Panel discussion

16:30-16:40 **Coffee break**

16:40-17:35 **DEBATE 2 – Future 2nd and 3rd line treatment of r/r aggressive B-cell NHL: auto and allo-transplant, bispecifics, or CARs?**
Chair: John Gribben (London)

16:40-16:45 Introduction John Gribben (London)

Audience votes

16:45-16:55	Allo-transplant	Bertram Glass (Berlin)
16:55-17:05	Bispecific antibodies	Martin Hutchings (Copenhagen)
17:05-17:15	CAR T-cells	Marie José Kersten (Amsterdam)

Audience votes again

17:15-17:35	Discussion	
17:35-18:25	ROUNDTABLE 2 – CARs in solid tumours Chair: Michael Hudecek (Würzburg)	
17:35-17:40	Introduction	Michael Hudecek (Würzburg)
17:40-17:50	GD2-targeting CAR T-cells in childhood tumours	Franco Locatelli (Rome)
17:50-18:00	CAR T-cells for treatment of atypical teratoid/rhabdoid tumours	Concetta Quintarelli (Rome)
18:00-18:05	<u>Brief oral communication</u> <i>Development of Combination Therapy with Oncolytic Viruses and PSMA-Specific CAR T for Prostate Cancer Eradication</i>	Sergey Kulemzin (Novosibirsk)
18:05-18:15	Making CAR T-cells last	Karin Straathof (London)
18:15-18:25	Discussion	

18:25-18:45 **MEET THE EXPERT'S FLASH TALKS**

18:25-18:30	NK cell CARs	Ulrike Köhl (Leipzig)
18:30-18:35	Bispecific CAR T-cells	Peter Borchmann (Cologne)
18:35-18:40	Sleeping Beauty	Michael Hudecek (Würzburg)
18:40-18:45	Point of care production of CAR T-cells	Alvaro Urbano-Ispizua (Barcelona)

To learn more and get answers to all your questions, make sure you pre-register to join the live Meet the Expert session of your choice.

18:55-19:55 **Simultaneous Meet the Expert Sessions:**

1. NK cell CARs	Ulrike Köhl (Leipzig)
2. Bispecific CAR T-cells	Peter Borchmann (Cologne)
3. Sleeping Beauty	Michael Hudecek (Würzburg)
4. Point of care production of CAR T-cells	Alvaro Urbano-Ispizua (Barcelona)

Thursday, September 9, 2021

13:10-14:10 Mentored Poster Walk

Leaders: Michael Hudecek (Würzburg), Alvaro Urbano-Ispizua (Barcelona)

SESSION V – Acute lymphoblastic leukaemia (ALL): the role of CARs and Bispecifics - lessons from paediatric haematology

Chairs: Peter Bader (Frankfurt), Jochen Büchner (Oslo)

14:20-14:25	Introduction	Peter Bader (Frankfurt), Jochen Büchner (Oslo)
14:25-14:35	Interactive case: A child with an isolated extramedullary 2 nd ALL relapse	Jochen Büchner (Oslo)
14:35-14:55	Case-based lecture: CAR T-cell therapy in childhood ALL: what can we learn for adult patients?	Peter Bader (Frankfurt)
14:55-15:15	Case-based lecture: CAR-T after allogeneic transplant	André Baruchel (Paris)
15:15-15:35	Case-based lecture: CAR-T for bridging to allogeneic transplant or repeated CARs?	Sara Ghorashian (London)
15:35-15:45	Interactive case: A child with a CNS relapse post CAR-T cell therapy	Jochen Büchner (Oslo)
15:45-16:20	Panel discussion	
16:20-16:30	Coffee break	

SESSION VI – Perspectives: CARs and bispecifics for haematological malignancies

Chairs: Cameron Turtle (Seattle), Marion Subklewe (Munich)

16:30-16:35	Introduction	Cameron Turtle (Seattle), Marion Subklewe (Munich)
16:35-16:55	Perspectives: Mantle Cell Lymphoma and Follicular Lymphoma	Marie José Kersten (Amsterdam)
16:55-17:15	Perspectives: CAR-T approaches for T-cell malignancies	Paul Maciocia (London)
17:15-17:35	Perspectives: Acute Myeloid Leukaemia	Chiara Bonini (Milan)
17:35-17:55	Perspectives: Chronic Lymphocytic Leukaemia	Cameron Turtle (Seattle)
17:55-18:30	Panel discussion	
18:30-19:00	Keynote lecture Chairs: Ulrich Jäger (Vienna), Marie José Kersten (Amsterdam)	
18:30-18:35	Introduction	Ulrich Jäger (Vienna), Marie José Kersten (Amsterdam)
18:35-18:55	The role of CAR T-cell therapy in cancer in 2030	Carl June (Philadelphia)
18:55-19:00	Discussion	
19:00-19:05	Closing remarks: Peter Borchmann, Ulrich Jäger, Marie José Kersten	

MEETING CLOSURE